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Abstract
Despite the crucial role of the liver in glucose homeostasis, a detailed mathematical model of human hepatic glucose
metabolism is lacking so far. Here we present a detailed kinetic model of glycolysis, gluconeogenesis and glycogen
metabolism in human hepatocytes integrated with the hormonal control of these pathways by insulin, glucagon and
epinephrine. Model simulations are in good agreement with experimental data on (i) the quantitative contributions of
glycolysis, gluconeogenesis, and glycogen metabolism to hepatic glucose production and hepatic glucose utilization under
varying physiological states. (ii) the time courses of postprandial glycogen storage as well as glycogen depletion in
overnight fasting and short term fasting (iii) the switch from net hepatic glucose production under hypoglycemia to net
hepatic glucose utilization under hyperglycemia essential for glucose homeostasis (iv) hormone perturbations of hepatic
glucose metabolism. Response analysis reveals an extra high capacity of the liver to counteract changes of plasma glucose
level below 5 mM (hypoglycemia) and above 7.5 mM (hyperglycemia). Our model may serve as an important module of a
whole-body model of human glucose metabolism and as a valuable tool for understanding the role of the liver in glucose
homeostasis under normal conditions and in diseases like diabetes or glycogen storage diseases.
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Introduction
The human plasma glucose is kept in a narrow range between
minimum values of ,3 mM after prolonged fasting or extensive
muscle activity and maximum values of ,9 mM reached
postprandially [1,2]. Homoeostasis of plasma glucose is crucial for
the organism: Hyperglycemia results in non-enzymatic glycosyla-
tion (glycation) and thus loss-of-function of proteins [3], glucose
induced oxidative damage [4,5] and other adverse effects [6,7].
Hypoglycemia leads to an under-supply of tissues with glucose and
is thereby of particular danger for neuronal cells, erythrocytes and
fibroblasts, using glucose as dominant or even exclusive energy-
delivering fuel under normal physiological conditions.
The liver is a central player in buffering plasma glucose
contributing either by net hepatic glucose utilization (HGU) or
net hepatic glucose production (HGP) depending on the plasma
glucose level exceeding or falling below a critical threshold value (in
the following referred to as ‘set point’) of ,6 mM. Switching
between HGP and HGU is therefore a switch between positive (i.e.
export of glucose) and negative (i.e. import of glucose) net hepatic
glucose balance. This crucial metabolic function of the liver is
performed by hepatocytes which exhibit high capacity of glycogen-
esis, glycogenolysis, glycolysis and gluconeogenesis enabling them to
transiently store substantial amounts of glucose as glycogen, to
synthesize glucose from lactate, glycerol and glucoplastic amino
acids and to convert excess glucose into triglycerides [2,8,9].
Glucose homeostasis is controlled by several hormones, with
insulin and glucagon being the main counteracting players [1,10].
Insulin is the only known hormone lowering blood glucose,
whereas multiple glucose increasing hormones exist. Glucagon
plays the primary role in counter-regulation to hypoglycemia.
Epinephrine has a secondary role, becoming critical under
impaired glucagon responses, but with reduced effectiveness
compared to glucagon [11–13]. Other counter-regulatory hor-
mones like cortisol or thyroxin play only a minor role for the liver
[10,12,13]. The plasma concentrations of insulin, glucagon and
epinephrine change as direct response to varying blood glucose
[1,10]. In the liver insulin increases the activity of glucose utilizing
pathways (HGU, glycolysis, glycogenesis) and decreases glucose
producing pathways (HGP, gluconeogenesis, glycogenolysis),
whereas glucagon and epinephrine have contrary effects. Main
targets of the gluco-regulatory hormones are key interconvertible
enzymes of glucose metabolism like pyruvate kinase or glycogen
synthase. The kinetics of the interconvertible enzymes, and
consequently also the hepatic glucose metabolism, depends on
their phosphorylation state [2,14] which is altered by the
hormones.
Despite the crucial role of the liver for glucose homeostasis, a
detailed mathematical model of human glucose metabolism of the
liver, indispensable for understanding the hepatic role under
normal and impaired conditions like occurring in diabetes, has not
been developed yet. Available kinetic models of hepatic glucose
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parts of the glucose metabolism [19], or lump reactions [20,21].
Furthermore, all available models concentrate on the glucose-
insulin system, and ignore the crucial insulin antagonists glucagon
and epinephrine [15–19], or do not include hormonal regulation at
all [20,21]. All mentioned models with exception of [19] ignore the
crucial dependency of enzyme kinetics on the respective phosphor-
ylation state of the enzyme completely, an essential mechanism for
short term regulation in hepatic glucose metabolism.
Here, we present the first model of hepatic glucose metabolism
in molecular detail, which includes the crucial control of hepatic
glucose metabolism by insulin, glucagon and epinephrine via
changes in phosphorylation state of key enzymes based on a new
concept of linking hormonal regulation with metabolism.
Methods
The model of human hepatic glucose metabolism (Figure 1)
consists of 49 localized metabolites (Text S1) and 36 reactions
(Text S2) compartmentalized into cytosol, mitochondrion and
blood. Abbreviations of metabolites and reactions are defined in
the legend of Figure 1. All reactions and transporters are modeled
with individual kinetics (Text S3) with parameters from literature
research or by fitting to experimental metabolite and flux data
(Equation 1, Dataset S1). An annotated SBML of the model is
provided in the supplement (Dataset S2). The model includes
regulation via allosteric mechanisms (Text S4) and regulation by
hormones via phosphorylation and dephosphorylation of inter-
convertible enzymes (Text S5). Enzymes regulated by allosteric
mechanisms are GK, GS, GP, PFK1, PK, PC, PDH, FBP1 and
FBP2. Enzymes regulated via changes in phosphorylation state are
GS, GP, PFK2, FBP2, PK and PDH. All model fluxes are given in
mmol
kgbw min
(bw=bodyweight).
Kinetic parameters
The detailed kinetic equations for the reactions and transporters
(Text S3) are specific for human liver and based on extensive
literature research. All kinetic parameters except the maximal
velocities Vmax are based on literature data with references given
in the respective rate equation. All Vmax values in the model were
determined by fitting simulated model fluxes vsim
k (Vmax) to
experimentally determined fluxes vex
k and simulated model
metabolite concentrations csim
i (Vmax) to experimentally measured
concentrations cex
i .
The fit procedure minimizes the sum of quadratic relative
differences in fluxes and concentrations, divided by the total
number of experimental fluxes Nv or respectively the total number
of experimental concentrations Nc (Equation 1). Relative differ-
ences were used to avoid a domination of the optimization by large
absolute values and to have dimensionless quantities. The
contributions of fluxes and concentrations to least-square fit
function were weighed equally (l~1) assigning same relevance to
fluxes and concentrations.
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The experimental flux data vex
k was human specific (Dataset S1),
the metabolite concentrations cex
i were taken from human and rat
liver and are given in (Text S1, Dataset S1). Equation 1 was
minimized using the MATLABH Optimization Toolbox (con-
straint nonlinear optimization) and resulted in a final value of
f min(Vmax)~0:65, indicating that the overall remaining relative
deviations of theoretical values from experimental ones were lower
than a factor of 2. The fitted Vmax values are given in Text S2.
Integration of differential equations
For the time course and steady state simulations the differential
equation system (Text S3) was integrated with a variable-order
solver for stiff problems based on numerical differentiation
formulas with absolute integration tolerance absTol~10{10 and
relative integration tolerance relTol~10{4 (ode15s MATLABH
R2011a, MathWorks). Initial concentrations for all simulations are
given in Text S1. Variation in blood glucose and glycogen are
given in the respective figure legends. The external concentrations
of blood glucose and lactate were kept at fixed values in all
simulations as their time evolution in the blood depends on the
metabolic activity of various organs not considered in this model.
The cellular redox state (given by the concentrations of NAD and
NADH) and cellular energy state (given by the concentrations of
the adenine nucleotides) were kept constant during all simulations.
Steady state solutions are defined as states with absolute changes
in every concentration smaller than absTol for a time interval
§2000s. Steady state solutions were tested to be stable against
small changes in initial concentrations (1%). All conservation
entities were tested to be constant within the tolerances over the
integration.
Hormonal regulation (GHR)
As the release of hormones and their elimination from the
plasma are not part of the model, the relationships between plasma
glucose level and hormone levels (Figure 2) are described by
phenomenological functions called glucose-hormone responses
(GHR). The GHRs are sigmoid functions ranging between basal
hormone concentration hbase and maximal hormone concentra-
tion hmax, monotonically increasing with increasing blood glucose
Author Summary
Glucose is an indispensable fuel for all cells and organs,
but at the same time leads to problems at high
concentrations. As a consequence, blood glucose is
controlled in a narrow range to guarantee constant supply
and on the other hand avoid damages associated with
elevated glucose levels. The liver is the main organ
controlling blood glucose by (i) releasing newly synthe-
sized or stored glucose in the blood stream when blood
glucose is low (ii) using and storing glucose when blood
glucose is elevated. These processes are regulated by
hormones, in particular insulin, glucagon and epinephrine.
We developed the first detailed kinetic model of this
crucial metabolic system integrated with its hormonal
control and validated the model based on a multitude of
experimental data. Our model enables for the first time to
simulate hepatic glucose metabolism in depth. Our results
show how due to the hormonal control of key enzymes
the liver metabolism can be switched between glucose
production and utilization. We provide an essential model
to analyze glucose regulation in the normal state and
diseases associated with defects in glucose homeostasis
like diabetes.
Kinetic Model of Human Hepatic Glucose Metabolism
PLoS Computational Biology | www.ploscompbiol.org 2 June 2012 | Volume 8 | Issue 6 | e1002577Figure 1. Overview of human hepatocyte model consisting of glycolysis, gluconeogenesis and glycogen metabolism. Metabolic
model compartmentalized in blood, cytosol and mitochondrion. Key enzymes of HGP are shown in red, key enzymes of HGU in green. Enzymes
regulated via allosteric mechanisms are marked with a red A, interconvertible enzymes with a yellow P. Insulin, glucagon and epinephrine regulate
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and epinephrine (Equation 3). The GHRs were determined by
least-square fit to oral glucose tolerance tests and hypoglycemic,
hyperinsulinemic clamp studies (Table 1, Dataset S1). The
parameters correspond to hmax, hbase, the inflection point k and
the Hill coefficient n which determines the steepness of the
sigmoidal hormone response.
h1(glc)~hbasez(hmax{hbase)
glcn
kn
hzglcn ð2Þ
h2(glc)~hbasez(hmax{hbase)(1{
glcn
kn
hzglcn) ð3Þ
Experimental data and standard deviations (Dataset S1) were
extracted from figures, tables and supplemental information. Data
points correspond to mean data for multiple subjects from the
studies. No data points were omitted.
Phosphorylation state (c) of interconvertible enzymes
The short-term effects of insulin, glucagon and epinephrine
result from changes in the phosphorylation state of key intercon-
vertible enzymes of glucose metabolism, namely GS, GP, PFK2,
FBP2, PK and PDH. The interconvertible enzymes exhibit
different kinetic properties in the phosphorylated state (P) and
dephosphorylated state (DP), thus carrying different fluxes in the
phosphorylated state (vp) and dephosphorylated state (vdp). The
resulting effective kinetics vic (Equation 4) is the linear combina-
tion of vp and vdp dependent on the phosphorylation state c[ 0,1 ½  ,
with c being the phosphorylated and (1{c) the dephosphorylated
fraction of the enzyme.
vic~c:vpz(1{c):vdp ð4Þ
The phosphorylation state c is a phenomenological function of
insulin, glucagon and epinephrine (Equation 5). Insulin decreases c,
whereas glucagon and epinephrine increase c. Epinephrine acts as a
backup system for glucagon with reduced effectiveness aepi~0:8.
Only the currently dominating hormone (glucagon or epinephrine)
was taken into account (max). The hormonal dependencies on the
phosphorylation state were modeled by a Michaelis-Menten like
hyperbolic function with half-saturation at h~kc(hmax{hbase)
whereby the saturation parameter was set to kc~0:1 for all
hormones. The maximal basal hormone concentrations of the three
hormones (glumax,glubase,epimax,epibase,insmax,insbase) result from
the respective GHR curves and are given in Table 1.
c(ins,glu,epi)~0:5:
1zmax
glu
kc(glumax{glubase)zglu,
aepi:epi
kc(epimax{epibase)zepi
0
B @
1
C A
{ ins
kc(insmax{insbase)zins
0
B B B B B @
1
C C C C C A
ð5Þ
We assumed that for given hormoneconcentrations the fraction c of
all interconvertible enzymes is equal.
Hepatic glucose production, gluconeogenesis and
glycogenolysis
Experimental data (Table 2, Dataset S1) was extracted from
figures and tables of 25 independent studies with different tracer
methods. See [2] for review and Table 2 for detailed references,
used methods and experimental data. Every data point is the
mean for multiple subjects from one of the studies. No data points
were omitted.
Glycogenolysis and glycogen synthesis
Experimental data (Dataset S1) was extracted from figures and
tables from [22] (individual data) and [23] (mean person data
with STD) for the glycogenolysis and from [8,24,25] (mean
person data) for the glycogen synthesis. The only difference
between model simulations in states of either net glycogen
synthesis or net glycogenolysis simulations are differences in the
initial glycogen and blood glucose concentrations. Experimental
data for the mixed meal and hyperglycemic, hyperinsulinemic
clamp simulations were extracted from [26] using the experi-
mental time courses of glucose as model input. Insulin and
glucagon time courses were predicted with the respective
hormone dose response curves (Equation 2 and Equation 3).
Simulations were started the from initial glycogen concentrations
reported in the experiments.
Role of insulin and glucagon for HGP
Experimental data (Dataset S1) were extracted from figures and
tables from [27]. Basal hormone concentrations of dogs and
humans differ due to difference in human and dog physiology.
Therefore, in model simulations of the human liver typical insulin
and glucagon concentrations for the basal glucose production rate
in humans were used (insulin 100
pmol
l
and glucagon 80
pmol
l
) and
concentration changes for the hormones expressed relative to these
basal values Changes in blood glucose were calculated from the
simulated HGP, for a mean bodyweight of mbw~75kg, blood
volume of Vblood~5l and whole-body basal glucose utilization rate
the glucose metabolism by changing the phosphorylation state c of key interconvertible enzymes, with insulin (c{+) decreasing and epinephrine
(cz+) and glucagon (cz) increasing c. See Methods for additional information. Reactions: (ALD) aldolase, (AK) adenylate kinase, (CS) citrate synthase,
(EN) enolase, (FBP1) fructose-1,6 bisphosphatase, (FBP2) fructose-2,6 bisphosphatase, (GAPDH) glyceraldehyde phosphate dehydrogenase, (G1PI)
glucose-1 phosphate 1,6-phosphomutase, (G6P) glucose-6 phosphatase, (GK) glucokinase, (GLUT2) glucose transporter 2, (GP) glycogen
phosphorylase, (GPI) glucose-6 phosphate isomerase, (GS) glycogen synthase, (LDH) lactate dehydrogenase, (MALT) malate transporter, (MDH)
malate dehydrogenase, (NDK) nucleoside diphospate kinase, (PC) pyruvate carboxylase, (PEPCK) phosphoenolpyruvate cyrboxykinase, (PEPT)
phosphoenolpyruvate transporter, (PDH) pyruvate dehydrogenase, (PFK1) phosphofructokinase 1, (PFK2) phosphofructokinase 2, (PGK)
phosphoglycerate kinase, (PGM) 3-phosphoglycerate mutase, (PK) pyruvate kinase, (PPASE) pyrophosphate phosphohydrolase, (PYRT) pyruvate
transporter, (TPI) triose phosphate isomerase, (UGT) UTP:glucose-1 phosphate uridylyltransferase. Metabolites: (13P2G) 1,3-bisphospho glycerate,
(2PG) 2-phospho glycerate, (3PG) 3-phospho glycerate, (ACoA) acetyl-coA, (Cit) citrate, (CoA) coenzyme A, (DHAP) dihydroxyacetone phosphate,
(Fru16P2) fructose-1,6 bisphosphate, (Fru26P2) fructose-2,6 bisphosphate, (Fru6P) fructose-6 phosphate, (Glc) glucose, (Glc1P) glucose-1 phosphate,
(Glc6P) glucose-6 phosphate, (GRAP) glyceraldehyde 3-phosphate, (Lac) lactate, (OA) oxalacetate, (Mal) malate, (P) phosphate, (PEP)
phosphoenolpyruvate, (PP) pyrophosphate, (Pyr) pyruvate, (UDP-Glc) UDP-glucose.
doi:10.1371/journal.pcbi.1002577.g001
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mmol
kgmin
. In Simulation 1 no experimental data was
taken into account, but only a drop in the respective hormones
during the infusion period (135–200 min) assumed. In Simulation
2 the experimentally observed changes in hormones and GU
relative to basal levels (mean of values during the pre-infusion
period) were used.
Hepatic glucose response coefficient (HGRC)
The HGRC defined by Equation 6 measures the change in
net hepatic glucose balance defined through the net rate of
g l u c o s ee x c h a n g eb e t w e e nh e p a t o c y t e sa n dt h eb l o o d
(vGLUT2(glc)) elicited by a small change in blood glucose
concentration. In model simulations, the HGRC was approx-
imated by a difference quotient and numerically calculated from
Figure 2. Glucose-Hormone Responses (GHR) of insulin, glucagon and epinephrine and phosphorylation state ª. Experimental data
from multiple studies based on oral glucose tolerance tests and hypoglycemic, hyperinsulinemic clamp studies and the corresponding fitted
GHR curves. Parameters for the GHR curves in Table 1 and experimental data in Dataset S1. (A) Glucagon GHR. Glucagon increases with
decreasing blood glucose from a basal concentration of 37.9 pmol/l to a maximal concentration of 190.0 pmol/l with the inflection point at
3.01 mM (B) Epinephrine GHR. Epinephrine increases with decreasing glucose from a basal concentration of 100 pmol/l to a maximal
concentration of 6090 pmol/l with the inflection point at 3.1 mM (C) Insulin GHR. Insulin increases with increasing glucose from a basal
concentration of 0 pmol/l to a maximal concentration of 818.9 pmol/l with the inflection point at 8.6 mM (D) Resulting phosphorylation state c
(Equation 5) based on the GHRs for insulin, glucagon and epinephrine decreasing with increasing glucose from phosphorylated to
dephosphorylated.
doi:10.1371/journal.pcbi.1002577.g002
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corresponds to the changes in HGU, for vGLUT2:ƒ0 to the
change in HGP.
HGRC(glc)~
dvGLUT2(glc)
dglc
&
DvGLUT2(glc)
Dglc
~
DvHGU(glc)
Dglc
VvGLUT2:w0
DvHGP(glc)
Dglc
VvGLUT2:ƒ0
8
> > <
> > :
ð6Þ
Table 1. Fit functions and parameters for the insulin,
glucagon and epinephrine GHR.
Hormone f max base k n Experimental Data
[pmol/l] [pmol/l] [mM]
insulin h1 818.9 0 8.6 4.2 [1,28,35–41]
glucagon h2 190 37.9 3.01 6.4 [1,28,35,37,38,40–46]
epinephrine h2 6090 100 3.1 8.4 [40,42–47]
doi:10.1371/journal.pcbi.1002577.t001
Table 2. Experimental data for HGP, gluconeogenesis (GNG), glycogenolysis (GLY).
Method Reference Time HGP GNG GLY GNG/HGP
[h] [mmol/kg(bw)/min] [mmol/kg(bw)/min] [mmol/kg(bw)/min] [%]
14C-acetate [48] 66 7.56 7.39 0.34 97
13C-NMR [22] 42–64 8.7 8.3 0.3 96
13C-glycerol MIDA [49] 60 7.87 7.71 1.58 98
13C-glucose MID [50] 40 9.8 9.1 1.1 92
2H2O [51] 42 - - - 93
2H2O [52] 40 7.93 7.13 0.8 90
14C -acetate [48] 14 12.5 3.6 9 28
14C -bicarbonate [53] 10–12 7.15 2.2 4.9 31
14C -bicarbonate [54] 12–14 8.3 2.6 5.5 31
14C -glucose [55] 12 8.8 4.5 4.3 51
13C-NMR [22] 22 12.2 7.9 4.3 64
13C-NMR [23] 23 8.9 6.1 2.8 70
13C-glycerol MIDA [49] 11 12.1 5.9 6.2 49
13C-glycerol [56] 10 11.7 4.9 6.8 41
13C-glucose MID [50] 12 12.9 5.3 7.7 41
13C-glucose [57] - 13.1 7.4 5.7 56
13C-glucose (a) [58] 18 8.5 5.9 2.6 59
13C-glucose (b) [58] 18 8.5 3.7 4.8 44
13C-glucose [59] 12 12.9 5.3 7.6 41
13C-glucose [59] 16 11.5 6.6 4.8 57
13C-glucose [59] 20 10 7.1 2.9 71
2H2O [51] 14 10.2 5.5 4.7 54
2H2O [51] 22 8.6 5.5 3.1 64
2H2O [60] 16 10 5.5 4.5 55
2H2O [60] 20 9 5.4 3.6 60
2H2O [60] 24 8.5 5.2 3.3 61
2H2O [61] 10 11.4 5.5 5.9 48
2H2O [62] 16 12.2 6.7 5.5 55
2H2O [63] 15 12.4 5.6 6.7 45
2H2O [56] 10 12.2 7.4 3.8 60
2H2O [64] 11 10.4 5.8 4.65 55
2H2O [65] 16 9.8 5 4.8 51
2H2O [66] 15 17.7 12.7 5 71
2H2O [67] 16 17.5 8.9 8.2 51
2H2O [68] 17 11.9 4.6 7.3 38
doi:10.1371/journal.pcbi.1002577.t002
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The reactions for citrate efflux, oxaloacetate influx and
acetyl-CoA flux were included in the model, to test the model
under various TCA cycle loads and changes in acetyl-CoA
demand and production being a necessary condition in the
model development of a functioning model of hepatic glucose
metabolism under typical physiological TCA cycle loads. The
malate-aspartate shuttle (MALT) including cytosolic and mito-
chondrial malate dehydrogenase (MDH) was not modeled in
detail. Thus, the rate of the cytosolic isoform of the PEPCK was
put to directly depend on mitochondrial oxaloacetate concen-
tration. For the actual simulations these boundary fluxes where
set to zero.
Metabolic Control Analysis (MCA)
To characterize the regulatory importance of various reactions
in different states of hepatic glucose metabolism we used
metabolic flux response coefficients Ri
k (Equation 7), describing
how the flux rate of an arbitrary reaction i changes in response to
a small change in the maximal activity Vmax of an arbitrary
reaction k.
Ri
k~
Lln(vi)
Lln(Vmax,k)
&
(vi(Vmax,kzDVmax,k){vi(Vmax,k))=vi(Vmax,k)
DVmax,k=Vmax,k
ð7Þ
Response coefficients with respect to the maximal activities of all
enzymes were calculated at varying values of external glucose and
cellular glycogen content for key fluxes of hepatic glucose metabolism
(Figure S9): hepatic glucose uptake/release (vGLUT2), gluconeogene-
sis/glycolysis (vGPI) and glycogenolysis/gluconeogenesis (vG1PI).
Results
We present the first detailed kinetic model of human hepatic
glucose metabolism integrated with the hormonal regulation via
insulin, glucagon and epinephrine (Figure 1 and Methods) via a
new concept of changes in phosphorylation state (Figure 2 and
Methods). The model was validated with quantitative and
qualitative experimental data from a multitude of studies on
hepatic glucose metabolism in overnight fasting, short term fasting
and postprandial glycogen storage (Table 3, Figure 3, Figure 4,
Table 3. Comparison of model predictions and experiments.
Item Model Experimental data References
A HGP at 25.5 mM blood glucose
HGU at 8 mM blood glucose
,4 mmol/kg(bw)/min HGU
at 8 mM blood glucose
,8.5 mmol/min/kg(bw) splanchnic glucose
utilization (SGU) at 8 mM glucose (difference
between 7 mmol/min/kg (bw) splanchnic
glucose production and 15.5 mmol/min/kg
(bw) splanchnic glucose uptake at
physiological insulin of 300 pmol/l at 8 mM)
[29]
HGP/HGU set point: 6.6 mM glucose
for half-filled glycogen; 7.3 mM
glucose for filled glycogen stores;
HGU,SGU due to glucose usage of the gut [29]
B set point glycogenesis/
glycogenolysis
set point at 5.1 mM set point at ,5m M( ,6 h postprandially) [8,25]
C rate of glycogenesis and
cumulative glycogen content
increase from 250 to 350 mM
glycogen at 7 mM (250 to 370 mM
glycogen at 8 mM) glucose in 4 h
with linear rate of glycogenesis
increase from ,200 to ,300 mM glycogen
at ,7–8 mM glucose in 4 h with linear
rate of glycogenesis
[8,24,25]
D HGP after short term starvation
and contributions from
gluconeogenesis/glycogenolysis
,8.5 mmol/kg(bw)/min HGP for short
term starvation (20 h at 3 mM glucose)
with 95% HGP from gluconeogenesis
(5% HGP from glycogenolysis)
7.56–9.8 mmol/kg(bw)/min HGP with 92–97%
gluconeogenesis (2–8% HGP from glycogenolysis)
[2,22,50,51].
E glycogen decrease
(overnight fast)
decrease in glycogen from filled
(500 mM) to half-filled glycogen stores
(250 mM) in 16 h at 4.5 mM glucose
decrease in glycogen from almost filled
stores to ,half-filled (200–250 mM)
glycogen in around 18–20 h
[22]
rate of glycogenolysis almost constant
and only decreasing at low glycogen
concentrations
rate of glycogenolysis almost constant
and only decreasing at low glycogen
concentrations
[22]
F HGP for overnight fast and
contributions from
gluconeogenesis/glycogenolysis
,13.5 mmol/kg(bw)/min HGP at ,3.8 mM
blood glucose with ,5.5 mmol/kg(bw)/min
glycogenolysis (41%) and ,8 mmol/min/
kg(bw) gluconeogenesis (59%)
,12 mmol/kg(bw)/min HGP with nearly
equal contributions of glycogenolysis and
gluconeogenesis with ,6 mmol/kg(bw)/min
(50%)
[2]
G glycogenesis via direct
and indirect pathway
equal rates of HGU and gluconeogenesis
of 4 mmol/kg(bw)/min at 8 mM glucose
(equal contributions of direct and
indirect pathway)
,equal amounts of glycogenesis via direct
(10 g) and indirect pathway (15 g) after oral
glucose load
[69]
H rate of glycogenolysis ,constant rate of glycogenolysis for
partially filled glycogen stores and a
decrease in glycogenolysis only for
glycogen below ,150 mM
,constant rate of glycogenolysis for partially filled
glycogen stores and a decrease in glycogenolysis only
for low glycogen
[22,23]
doi:10.1371/journal.pcbi.1002577.t003
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central role of the liver in glucose homeostasis, especially the
hepatic capability (i) to switch between an anabolic glucose mode
(HGP) to a catabolic glucose mode (HGU) depending on the blood
glucose concentration and hormonal signals (iii) to use glycogen as
glucose buffer in this process (iii) to respond to counteracting
changes in blood glucose with changes in glucose production
(HGP) and glucose utilization, especially in the fasting and
postprandial physiological state (Figure 5).
Hormonal regulation of glucose metabolism
The plasma concentrations of the gluco-regulatory hormones
change with changes in plasma glucose concentration. With
increasing glucose the insulin level increases (Figure 2C), whereas
the levels of glucagon (Figure 2A) and epinephrine (Figure 2B)
decrease. Consequently, the phosphorylation state c of the
interconvertible enzymes (Figure 2D, Equation 5) changes from
phosphorylated (94% at 2 mM) to dephosphorylated (5% at
14 mM) with increasing blood glucose. Changes in the phosphor-
Figure 3. HGP, gluconeogenesis (GNG), glycogenolysis (GLY) and GNG/HGP in short term fasting over 70 h. Experimental data from 25
separately published studies based on a variety of different labeling approaches listed in Table 2 and given in Dataset S1. Simulation time courses
(dashed lines) start at t=10 h with glycogen partially filled glycogen stores (350 mM). Blood glucose is varied between 3.6 mM (red) and 4.6 mM
(green) in steps of 0.2 mM. The blue curve corresponds to a situation where the plasma glucose concentration changes over the time of fasting from
4.2 mM to 3.6 mM in 70 h. (A) HGP decreases with increasing fasting time and reaches constant levels after around 25 h. With decreasing blood
glucose HGP increases. (B) gluconeogenesis is almost constant over time. With decreasing blood glucose GNG increases (C) glycogenolysis decreases
over time with decreasing glycogen. Lower blood glucose results in an initially higher GLY rate (D) GNG/HGP. The relative contribution of
gluconeogenesis to the hepatic glucose production increases over time. After 40 h fasting over 90% of the produced glucose comes from de novo
synthesis.
doi:10.1371/journal.pcbi.1002577.g003
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PLoS Computational Biology | www.ploscompbiol.org 8 June 2012 | Volume 8 | Issue 6 | e1002577Figure 4. Glycogen metabolism and hormone perturbations. (A) Decrease in glycogen during short term fasting over 60 h. Experimental data
from [22] (individual data) and [23] (mean data with STD) given in Dataset S1. Simulation time courses (dashed lines) start from filled glycogen stores
(500 mM). Blood glucose is varied between 3.6 mM (red) and 5.0 mM (green) in steps of 0.2 mM (black). The blue curve corresponds to a situation
where the plasma glucose concentration changes from initially 5 mM to 3.6 mM in 60 h. Higher blood glucose results in a slower decrease in
glycogen. (B) Increase in glycogen after a glucose load. Experimental data from [8,24,25] given in Dataset S1. Simulation time courses (dashed lines)
start from initial glycogen concentration of 200 mM. Blood glucose concentrations are varied between 5.5 mM (red) and 8.0 mM (green) in steps of
0.5 mM (black). The blue line corresponds to 7 mM. Higher blood glucose results in a faster increase in glycogen after a glucose load. (C) Change in
HGP and plasma glucose in insulin deficiency. Insulin (blue) and glucagon (red) time courses for an idealized hormone perturbation (left), the
experimental data from [27] (middle), and a simulation taking the experimental profile of hormones and glucose utilization into account are shown in
the top row. Middle row depicts the time courses of HGP (red) and whole-body glucose utilization GU (black). Bottom row shows the resulting
change in plasma glucose as a consequence of the changes in HGP. Insulin deficiency increases HGP relative to GU resulting in an increase in plasma
glucose. After insulin normalization HGP decreases and falls below GU due to the increased blood glucose. (D) Changes in HGP during the infusion
period (135–200 min) relative to the pre-infusion period (85–135 min) for the simulations and experiments and the various hormone perturbations.
Saline infusion (Figure S1) and somatostatin infusion with insulin and glucagon restauration (Figure S5) have no effect on basal HGP. Insulin and
glucagon deficiency (Figure S2) and glucagon deficiency alone (Figure S3) decrease HGP relative to basal values. Insulin deficiency increases basal
HGP (Figure 4C, Figure S4).
doi:10.1371/journal.pcbi.1002577.g004
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the respective enzymes (see Equation 4). Due to the higher activity
of the interconvertible enzymes of HGP (GP and FBP2) in the
phosphorylated form and the increased activity of the enzymes of
HGU (GS, PFK2, PDH, PK) in their dephosphorylated form (Text
S5), the hepatic glucose metabolism is shifted from a glucose
producing phenotype (HGP) under low glucose concentrations to a
glucose consuming phenotype (HGU) at hyperglycemia. This
change from an anabolic metabolism of glucose production
(HGP) to a catabolic mode of glucose utilization (HGU) is a short
term adaptation via changes in the kinetic properties of crucial
enzymes of glucose metabolism. By adapting the HGP/HGU,
gluconeogenesis/glycolysis and glycogen metabolism to the current
hormonal signals and blood glucose concentration, the liver is able
to fulfill its important role in glucose homeostasis in a variety of
physiological states ranging from hypoglycemic states in overnight
and short term fasting to hyperglycemic states postprandial.
HGP, gluconeogenesis and glycogenolysis in short term
fasting
The liver is the main glucose supplier in overnight fasting and
short term fasting. The produced hepatic glucose (HGP, Figure 3A)
results either from de novo synthesis via gluconeogenesis (GNG,
Figure 3B) or from degradation of hepatic glycogen via
glycogenolysis (GLY, Figure 3C). The relative contributions of
Figure 5. HGP/HGU and HGRC. Steady state solution of time course simulations under constant glycogen and blood glucose concentration (every
data points correspond to a single simulation to steady state). Glycogen is varied between 0 and 500 mM in steps of 5 mM, blood glucose is varied
between 2 and 14 mM in steps of 0.05 mM. (A) HGP (red)/HGU (green) ([
mmol
kgbw min
]) corresponding to GLUT2 flux. The liver switches between HGP and
HGU depending on the blood glucose and glycogen. The set point varies between 5.4 mM for empty and 7.5 mM for completely filled glycogen
stores (6.6 mM at glycogen 250 mM). (B) HGRC ([
ml
kgbw min
]). Response of the liver to changes in the blood glucose. Two main regions of high
response exist: A hypoglycemic region below 4 mM, and a hyperglycemic region above 8 mM glucose. (C) gluconeogenesis (red)/glycolysis (green)
([
mmol
kgbw min
]) corresponding to glucose-6p isomerase (GPI) flux. The gluconeogenesis/glycolysis set point varies between 8.8 mM for empty and
7.0 mM for filled glycogen stores. (D) glycogenolysis (red)/glycogenesis (green) ([
mmol
kgbw min
]) corresponding to flux through glucose-1p isomerase (G1PI).
doi:10.1371/journal.pcbi.1002577.g005
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with gluconeogenesis becoming more and more important,
whereas the share of glycogenolysis to HGP decreases (GNG/
HGP, Figure 3D).
The simulations for short term fasting under constant glucose
concentrations between 5 mM (green) and 3 mM (red), the normal
range of fasting glucose concentration [22,23], are in agreement
with the experimental data (Figure 3, Table 2). Taking into
account the gradual decrease in blood glucose concentration
during fasting from 5 mM to 3.6 mM (blue), an agreement
between simulation and experimental data is observed.
HGP decreases with ongoing fasting to a constant basal rate of
7–8
mmol
kgbw min
at around 40 h (Table 3D, Table 3F). With
increasing blood glucose HGP decreases. Gluconeogenesis rate is
constant for given blood glucose concentrations (see [2] for
review). Taking into account the gradual decrease in blood glucose
over fasting the rate of gluconeogenesis increases gradually (blue).
In contrast, glycogenolysis decreases sharply during fasting due
to the emptying glycogen stores (see also Figure 4A). As a
consequence, the fractional contributions of glycogenolysis and
glycogen synthesis to HGP shift from initially equal contribution of
both processes to glucose finally completely synthesized de novo.
Whereas after an overnight fast (,10 h) half of the HGP comes
from glycogenolysis [2], after 40 h fasting only 10% of HGP result
from glycogen, 90% from gluconeogenesis.
Glycogenolysis in short term fasting
Liver glycogen has an important role as a short term glucose
buffer for glucose homeostasis. At low blood glucose concentra-
tions, like in the fasting state or during extensive muscle activity,
glucose is released from glycogen (Figure 4A), whereas during
periods of high blood glucose like postprandial glycogen is
synthesized from glucose (Figure 4B).
Over 40–50 h short term fasting the glycogen stores are
emptied. During an overnight fast glycogen is utilized and the
resulting glucose from glycogenolysis is exported resulting in half-
filled glycogen stores after ,16 h (Table 3E). The rate of
glycogenolysis is almost constant and decreases only at low
glycogen concentrations (Table 3E).
The simulations for glycogen depletion under hypoglycemia
(Figure 4A) for glucose concentrations between 3.6 mM (red) and
5 mM (green) are in agreement with experimental data [22,23]. The
rate of glycogenolysis depends on the blood glucose concentration
(see also Figure 3C). With decreasing blood glucose concentration,
therateofglycogenolysisincreases, glycogenstoresareemptied faster.
As a consequence of the drop in glucose concentration over fasting,
simulations at low glucose concentration overestimate the decrease in
glycogen, simulations at high glucose concentrations underestimate
the depletion. When taking the gradual drop of blood glucose from 5
to 3.6 mM into account (blue), the concordance of simulations
experimental data further improved.
Glycogen synthesis postprandial
Blood glucose levels are elevated postprandial and glycogen is
stored via glycogen synthesis (Figure 4B). The simulations for
glycogen synthesis under hyperglycemia for different glucose
concentrations between 5.5 mM (red) and 8.0 mM (green) (normal
range of postprandial glucose concentrations) are in good
agreement with the experimental data [8,24,25], especially the
simulation at 7 mM (blue) representing a normal blood glucose
value postprandial. With increasing blood glucose the rate of
glycogen synthesis increases and the hepatic glycogen stores are
filled faster. For medium filled glycogen stores between 200 and
300 mM the rate of glycogen synthesis is constant for a given
blood glucose concentration.
To further evaluate the predictive capacity of our model, we
performed time-course simulations of experimentally determined
glycogen levels in dogs monitored under conditions of hypergly-
cemic, hyperinsulinemic clamps and administration of a mixed
meal diet [26], as can be seen from the respective figures in the
supplement (Figure S1, S2, S3, S4, S5, S6), our model simulation
were in good agreement with the measured time courses of insulin,
glucagon and glycogen. Of note, in these simulations none of the
data was used for the calibration of the model. Moreover,
successful simulation of these experiments under conditions where
the two hormones insulin and glucagon could be varied
independently from each other while in vivo their levels are
coupled by the glucose level of the blood demonstrates the validity
of the phenomenological glucose-hormone response functions
(Equation 2 and 3) and interconversion –versus-hormone function
c (Equation 5) used in our model.
Role of insulin and glucagon for HGP
To analyze the effects of insulin and glucagon on HGP classical
hormone perturbation experiments of hepatic glucose metabolism
were simulated [27]. In these experiments a deficiency in either
insulin or glucagon or both was achieved by somatostatin infusion,
an inhibitor of insulin and glucagon secretion, in combination with
hormone replacement infusions. Figure 4C depicts exemplarily the
effect of a transient drop of insulin which is characterized by a
marked increase in HGP and a consequent rise in plasma glucose
concentration. HGP and plasma glucose return to normal after the
perturbation. Simulations of other cases (saline control, insulin and
glucagon depletion, glucagon depletion and somatostatin in
combination with insulin and glucagon restoration) are depicted
in Figure S1, S2, S3 and S5, respectively. For all hormone
perturbations the time courses of HGP as well as glucose are in
good agreement with the experimentally observed changes.
Predicted changes in basal glucose production (HGP) are very
similar to the experimentally observed changes (Figure 4C). Insulin
and glucagon depletion or glucagon depletion alone reduce the
HGP to around 70% of basal values, insulin depletion increases
HGP to around 130%. Insulin and glucagon have a dramatic
effect on the human hepatic glucose metabolism, with basal
glucagon being responsible for about 30% of HGP and basal
insulin preventing increased HGP as a consequence of an
unrestrained glucagon action [27].
Glucose homeostasis by the liver at rapidly changing
blood glucose levels
The special role of the liver for glucose homeostasis results from the
ability to switch between an anabolic glucose producing mode (HGP)
to a catabolic glucose utilizing mode (HGU) depending on the blood
glucose concentration and hormonal signals. In this process the
hepatic metabolism is altered from glucose production via gluconeo-
genesis and glycogenolysis at hypoglycemia to glucose utilization via
glycolysis and glycogen synthesis at hyperglycemia – a short term
switch between metabolic pathways occurring in the range of minutes.
To analyze the temporal response of hepatic glucose metabo-
lism to rapid variations in the external glucose concentrations we
performed time-dependent simulations with a step-wise constant
concentration profile of blood glucose and constant internal
glycogen concentrations. (Figure S7 and S8). To evaluate the
impact of hormone induced fast changes in the phosphorylation
state of key regulatory enzymes on metabolic regulation we
performed these simulations also in the absence of this mode of
regulation in the glycogen metabolism, i.e. frozen phosphorylation
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regulation of these enzyme activities only by allosteric effects.
We found clear differences in the simulated time-courses (black
and red curves in Figure S7 and S8) indicating that hormonal
regulation contributes substantially in the rapid adaptation of the
network to abrupt changes of blood glucose. In both cases (i.e.
presence or absence of hormonal control) the simulation revealed
that even after changing the external glucose concentrations
abruptly by 2 mM and more a new steady state was reached
within several minutes.
Glucose homeostasis by the liver at slowly changing
blood glucose levels
Based on the above finding that the a new metabolic steady-
state (except for glycogen) is achieved within a few minutes after
abrupt changes of the blood glucose level it appeared justified to
treat the metabolic network as being in a quasi-steady state as long
blood glucose changes are slow and the glycogen pool is quasi
constant.
Hence, the quasi-steady state approximation was applied to
simulate HGP/HGU at varying concentrations of blood glucose
and cellular glycogen (Figure 5). In these calculations, the external
glucose concentration was varied between constant values of 2 to
14 mM and the glycogen concentration kept at constant values
between 0 and 500 mM. For each couple of glucose/glycogen
values the resulting HGP/HGU (Figure 5A), the contribution of
gluconeogenesis/glycolysis to HGP/HGU (Figure 5C), the con-
tribution of glycogenolysis/glycogen synthesis to HGP/HGU
(Figure 5D) and the ability of the liver to respond to changes in
blood glucose expressed through the response coefficient HGRC
(Figure 5B) in this quasi steady-state where analyzed. The fluxes
depicted Figure 5 for a given constant glucose and glycogen
concentrations are the reached steady state fluxes for this glucose
and glycogen concentrations.
The hepatic glucose metabolism switches between anabolic
HGP and catabolic HGU at blood glucose concentrations of
6.6 mM for half-filled glycogen stores (Figure 5A). The set point
above the normal glucose concentration of around 5–5.5 mM
[1,28] is in line with the role of the liver as glucose producer under
normoglycemic conditions [1,29]. The liver contributes to glucose
homeostasis by exporting glucose below the HGP/HGU set point
(red) and importing glucose above this threshold (green) (Table 3A).
With increasing blood glucose levels, HGP decreases and HGU
increases, in accordance with reported suppression of glucose
production and increase in HGU with increasing postprandial
glucose level [8]. Glycogen has almost no influence on HGU
whereas for low blood glucose concentrations HGP strongly
depends on glycogen due to increased contribution of glycogen-
olysis to HGP with increasing glycogen content (Figure 5D). For
low glucose concentrations the increase in glycogenolysis with
increasing glycogen is strongest for low glycogen levels, more
moderate for glycogen concentrations above 200 mM. HGP is
maximal for filled glycogen store and low blood glucose.
The switch between gluconeogenesis and glycolysis occurs at
8.5 mM glucose for half-filled glycogen stores (Figure 5C).
Gluconeogenesis and glycolysis rate are mainly determined by
the prevalent blood glucose and only marginally depend on
glycogen. Below 8 mM blood glucose gluconeogenesis is remark-
ably constant [2] (see also Figure 3B).
For plasma glucose levels below 5.1 mM glucose is released
from glycogen stores via glycogenolysis, above 5.1 mM glycogen is
synthesized for half-filled glycogen stores (Figure 5D, Table 3B)
with rates of glycogenesis and cumulative glycogen as reported
(Table 3C). In contrast to gluconeogenesis/glycolysis, glycogen
metabolism is markedly affected by the glycogen content.
Glycogenolysis is almost constant for partially filled glycogen
stores and decreases only for low glycogen concentrations
(Table 3H). Glycogenesis increases with increasing glucose
concentration (Figure 5D), which is in accordance with the view
that blood glucose determines the maximal rate of glycogenesis
[8].
Most interestingly the switching behavior for glycogenesis/
glycogenolysis and glycolysis/gluconeogenesis is very distinct, with
different set points and different dependencies on glucose.
Gluconeogenesis is almost constant for low blood glucose and
glycolysis increases with increasing glucose. In contrast glycogen-
olysis is almost constant for high blood glucose and increases with
decreasing blood glucose at low blood glucose. In combination of
the two processes a HGP/HGU output of the liver is generated
with a set point at normal blood glucose concentrations which is
able to react over the whole range of physiological glucose
concentrations (Figure 5A).
Direct and indirect glycogen synthesis
As a consequence of the different set points for gluconeogenesis/
glycolysis and glycogenesis/glycogenolysis, hepatic glycogen can
be synthesized via two alternative pathways: the direct pathway, in
which glucose taken from the blood (HGU) is directly stored as
glycogen above the gluconeogenesis/glycolysis set point of ,8.5–
8.8 mM; the indirect pathway, in which glucose synthesized via
gluconeogenesis, is stored as glycogen for blood glucose concen-
trations between 5 mM and the HGP/HGU set point of ,6.6–
7 mM; In the intermediate region between the set points of HGP/
HGU and gluconeogenesis/glycolysis glycogen is synthesized via
the direct and indirect pathway with varying contributions [8]
(Table 3G).
Response coefficients
The effects of changes of Vmax values on HGP/HGU,
gluconeogenesis/glycolysis and glycogenolysis/gluconeogenesis
were analyzed via response coefficients [30] (Figure S9, Equation
7). The important findings of this analysis are as follows: (i) The
effect of changes in the Vmax is strongly dependent on the external
concentration of glucose and to a much lesser extent on the
glycogen level. (ii) Under hypoglycemic conditions main control of
hepatic glucose metabolism is exerted by a completely different set
of reactions than in hyperglycemia. (iii) The response of the
opposing pathway couples gluconeogenesis/glycolysis is very
different to the glycogenolysis/gluconeogenesis. (iv) A small group
of enzymes catalyzing irreversible reaction steps (GK, G6PASE,
GP, PFK1, FBPASE1, PFK2, and FBPASE2) have a significant
influence on the hepatic glucose metabolism whereas the majority
of enzymes have only marginal effects. This control analysis is of
particular interest for gene expression studies of hepatic glucose
metabolism like for instance studies of circadian or feeding
induced changes in hepatic expression [31].
The liver – a glucose homeostate (HGRC)
The hepatic counter-regulatory capacity to changes in blood
glucose was evaluated using the HGRC (Equation 6, Figure 5B), a
measurement of the ability of the liver to react to changes in the
blood glucose with changes in HGP or HGU, respectively. Our
simulations showed that the liver is able to respond over the whole
range of physiological blood glucose concentrations with
HGRC(glc,glycogen)§1:9
ml
kg:min
being the lower limit, i.e. a
change of 0.01 mM in blood glucose results in a change of HGP/
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. Intriguingly, our
analysis suggest the counter-regulatory response of the liver to
variations in the external glucose concentration to be particularly
pronounced around the HGP/HGU set point at ,6.6 mM which
is flanked by a strong counter-regulatory response to hypoglycemia
and a weaker response to elevated blood glucose levels. The strong
counter-regulation to a decrease of blood glucose below 5 mM
results in an effective increase in HGP whereby the rise of HGP
depends on the glycogen content, with most effective counter-
regulation for filled glycogen stores. The liver counteracts falling
blood glucose levels to avoid hypoglycemia with a strong response.
Furthermore, an increased response to elevated blood glucose
levels of above 7.5 mM is seen enabling the hepatocyte to react
efficiently to elevated blood glucose levels as occurring postpran-
dially (6–10 mM). The hepatic glucose metabolism has ideal
regulatory properties to react to the typical physiological
challenges to glucose homeostasis: counter regulation to hypogly-
cemia in fasting and under extensive muscle activity and counter
regulation to postprandial increase in blood glucose.
Discussion
We present the first detailed model of human hepatic glucose
metabolism integrating hormonal regulation by insulin, glucagon
and epinephrine based on a novel concept to couple the level of
these hormones with the phosphorylation state of interconvertible
enzymes. This model enables for the first time the analysis of the
hepatic carbohydrate metabolism at molecular level, including
hormonal regulation. Furthermore, we provide a novel method to
integrate hormonal signals with metabolism based on changes in
phosphorylation state.
Model simulations are in good agreement with experimental
data from a multitude of studies by different laboratories,
researchers and methods. We want to emphasize, that the model
was not fitted to single study data, but instead, data from a
multitude of different studies covering various aspects of glucose
metabolism were used. Thereby, the fundamental properties of
human hepatic glucose metabolism and not individual study
properties could be captured. Remarkably, the agreement of
model simulations with numerous experimental and clinical
findings was achieved without any re-fitting of model parameters
and under neglect of other gluconeogenic substrates than lactate
and regulatory phenomena on slow timescales as insulin-depen-
dent changes in the expression level of metabolic enzymes. The
model clearly underlines the importance of short term regulation
of metabolism by interconvertible enzymes, being able to adapt
hepatic metabolism to hormonal signals and glucose levels, and in
this process being able to switch between anabolic and catabolic
modes even within metabolic pathways.
We simulated the response of the human liver to changes in
blood glucose under varying glycogen concentrations and assessed
the contributions of glycogen metabolism and glycolysis/gluco-
neogenesis to HGP/HGU. Thereby we provide essential data for
the understanding of the role of the liver in glucose homeostasis,
which is not accessible experimentally. The underlying metabolic
network reaches quasi-steady state within minutes after perturba-
tions in plasma glucose (see Figure S7 and Figure S8). The
dynamics of hepatic glucose metabolism is therefore mainly
determined by the depletion/filling of the glycogen stores and the
external glucose concentrations under normal conditions. As a
consequence, the quasi-steady state system responses, shown for
the key fluxes of the glucose metabolism in Figure 5, provide a
good approximation of the state of hepatic glucose metabolism at
given concentrations of blood glucose and temporary filling state
of the glycogen store.
Furthermore, we analyzed the hepatic response to changes in
blood glucose over the whole physiological range of blood glucose
concentrations (3–11 mM), thereby integrating the available
experimental data from the research field of hypoglycemia
(accessible with hypoglycemic, hyperinsulinemic clamps
,5.5 mM) and of elevated glucose concentrations (accessible with
oral glucose tolerance tests OGTT.5 mM).
A model is always an abstraction of reality describing a certain
subset of biological phenomena. The underlining assumptions are
crucial for to understand the range of application of the model and
the limitations. Main model assumptions and simplifications are (i)
usage of phenomenological functions to incorporate hormone-
induced signal transduction, (ii) a constant cellular redox- and
energy status (iii) modeling of an ‘average’ hepatocyte, i.e.
neglecting metabolic zonation of hepatocytes along the sinusoid
[32] and (iv) no inclusion of changes in the gene expression of
metabolic enzymes.
(i) A crucial part of this model is the phenomenological
description of signal transduction (c), which takes into account a
substantial body of qualitative knowledge about the effects of the
individual hormones on hepatic glucose metabolism. Due to the
lack of quantitative experimental data on signaling processes as,
for example, concentrations, activities and phosphorylation states
of key kinases and phosphatases at varying concentrations of
glucose, insulin, glucagon and combinations of these factors, a
more detailed description was not possible. The model reproduces
the experimentally observed dependency of glucose metabolism on
the hormones. Especially, the reproduction of the classical insulin
and glucagon perturbation experiments of [27], performed as
independent validation without taking into account in the
modeling process, underlines the validity of such a simplified
treatment of the signaling network in the case of the hepatic
glucose metabolism. Throughout the model the phosphorylation
state of all regulatory enzymes is the same at given concentration
of glucagon and insulin. This simplification could be the reason
why the activation of the glycogen synthase was overestimated in
mixed meal and clamp simulations. A second simplification was
that the fraction (c) of phosphorylated inter-convertible enzymes
follow instantaneously the hormone concentrations in the plasma
although signal transduction occurs in the range of some minutes
[33]. Including time-dependent changes of proteins involved in the
cAMP-dependent signaling cascade in a later and more advanced
version of the model should result in slightly different time-courses
of fluxes and metabolite concentrations elicited by abrupt changes
of external metabolite- and hormone concentrations. However,
the main results of this study refer to the normal physiological
situation where significant changes of the blood glucose level occur
in a time window of hours (Figure 3, 4 and 5) with the metabolic
network always being in quasi-steady state.
(ii) The model is limited to physiological states of the liver where
changes in the energy- and redox state can be neglected.
Normally, the hepatic energy state is decoupled from the hepatic
glucose metabolism, with b-oxidation of fatty acids providing ATP
and reduced redox equivalents (NADH). Consequently, the model
is not able to simulate conditions where this assumption of energy
decoupling is not valid, for example, under hypoxic or ischemic
conditions.
(iii) The presented model describes the metabolic net behavior
of the liver of a hepatocyte averaged over the liver and is therefore
able to simulate the net effect of the liver on glucose balance,
namely net HGP and net HGU. In reality the liver exhibits a
zonated structure with varying capacities of gluconeogenesis and
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effects brought about by an ensemble of hepatocytes equipped
with differing capacities of glucose metabolism cannot be
simulated with a model of a ‘mean’ hepatocyte. For example,
the remaining difference between absolute glucose production and
net glucose production (Figure S6) are due to the simultaneous
presence of hepatocytes with net HGP (peri-portal hepatocytes)
and HGU (peri-central hepatocytes).
(iv) Remarkably, the anabolic/catabolic switch was achieved by
fast changes in the phosphorylation state and allosteric regulation
of key enzymes of glucose metabolism without temporal changes in
gene expression, i.e. changes in the protein levels of enzymes. In
our opinion, changes in gene expression as observed to occur with
different period lengths during the day [31] play no crucial role in
short-term glucose homeostasis, a system which has to react to fast
changes in the minute range of glucose supply (postprandial) and
glucose demand (muscle activity) by an adaptation of metabolism.
Changes in gene expression play a role in adapting hepatic
metabolism on longer time scales to for example reduce futile
cycles in counteracting pathways (like down-regulation of gluco-
kinase and up-regulation of glucose-6 phosphatase under hypo-
glycemia) or match glucose metabolism to physiological require-
ments (up-regulating of glucose-6 phosphatase under
hypoglycemic conditions to increase gluconeogenesis). The strong
effects of such changes on hepatic glucose metabolism could be
seen in the analysis of the response coefficients.
Finally, it has to be noted, that our model comprises fairly active
futile cycles in the glycogen metabolism, the PFK1/FBPase1
system and between PEPCK and PK. During model building it
was tried to minimize these cycles. Reducing and removing
individual cycles in the modeling process compromised the ability
of the model to switch between glucose consuming and glucose
producing pathways, namely HGP/HGU, gluconeogenesis/gly-
colysis and glycogen synthesis/glycogenolysis. An essential prop-
erty of the model is the simultaneous activity of glycogen synthase
and glycogen phosphorylase and the accompanied futile cycle,
necessary to reproduce the experimental time-courses for glycogen
synthesis in fasting and postprandially.
Substrate cycling allows the system to react to fast changes in
metabolite levels, the concomitant adaptation of key enzymes via
phosphorylation or dephosphorylation causes an additional shift of
the net flux in the right direction (see Figure S7). Taken together,
metabolic regulation via phosphorylation/dephosphorylation of
key enzymes in combination with futile cycles plays a key role in
our model, in line with the results presented by Xu et al. [34].
Future work will apply the presented model to diseases of
glucose homeostasis like diabetes, integrate the model in models of
whole-body glucose metabolism and use individual patient data to
generate individualized hepatic glucose models and analyze inter-
individual differences in glucose metabolism.
Supporting Information
Dataset S1 Experimental data used in model building
and validation. Data spreadsheets for model concentrations, the
GHR dose response curves, the glycogen time courses in fasting
and postprandial, HGP fluxes, and for the simulations reproducing
experimental work by Cherrington and Krssak.
(ZIP)
Dataset S2 Model SBML. Annotated SBML of the model.
(XML)
Figure S1 Cherrington1976 Saline. Figure analog to
Figure 4C. (top row) Insulin (blue) and glucagon (red) time courses
for an idealized hormone perturbation (left), the experimental data
[27] (center), and taking the experimental profile of hormones and
glucose utilization into account (right). (middle row) Time course
of HGP (red) and whole-body glucose utilization GU (black) for
the respective hormone profiles. (bottom row) Resulting changes in
plasma glucose as a consequence of the changes in HGP for the
respective hormone profiles and HGP/HGU time courses.
Experimental data is provided in Dataset S1.
(TIF)
Figure S2 Cherrington1976 Insulin and glucagon defi-
ciency. Figure analog to Figure 4C. (top row) Insulin (blue) and
glucagon (red) time courses for an idealized hormone perturbation
(left), the experimental data [27] (center), and taking the experimental
profile of hormones and glucose utilization into account (right).
(middle row) Time course of HGP (red) and whole-body glucose
utilization GU (black) for the respective hormone profiles. (bottom
row) Resulting changes in plasma glucose as a consequence of the
changesinHGPfortherespectivehormoneprofilesandHGP/HGU
time courses. Experimental data is provided in Dataset S1.
(TIF)
Figure S3 Cherrington1976 Glucagon deficiency. Figure
analog to Figure 4C. (top row) Insulin (blue) and glucagon (red)
time courses for an idealized hormone perturbation (left), the
experimental data [27] (center), and taking the experimental
profile of hormones and glucose utilization into account (right).
(middle row) Time course of HGP (red) and whole-body glucose
utilization GU (black) for the respective hormone profiles. (bottom
row) Resulting changes in plasma glucose as a consequence of the
changes in HGP for the respective hormone profiles and HGP/
HGU time courses. Experimental data is provided in Dataset S1.
(TIF)
Figure S4 Cherrington1976 Insulin deficiency. Figure
analog to Figure 4C. (top row) Insulin (blue) and glucagon (red)
time courses for an idealized hormone perturbation (left), the
experimental data [27] (center), and taking the experimental
profile of hormones and glucose utilization into account (right).
(middle row) Time course of HGP (red) and whole-body glucose
utilization GU (black) for the respective hormone profiles. (bottom
row) Resulting changes in plasma glucose as a consequence of the
changes in HGP for the respective hormone profiles and HGP/
HGU time courses. Experimental data is provided in Dataset S1.
(TIF)
Figure S5 Cherrington1976 Somatostatin and insulin
and glucagon restoration. Figure analog to Figure 4C. (top
row) Insulin (blue) and glucagon (red) time courses for an idealized
hormone perturbation (left), the experimental data [27] (center),
and taking the experimental profile of hormones and glucose
utilization into account (right). (middle row) Time course of HGP
(red) and whole-body glucose utilization GU (black) for the
respective hormone profiles. (bottom row) Resulting changes in
plasma glucose as a consequence of the changes in HGP for the
respective hormone profiles and HGP/HGU time courses.
Experimental data is provided in Dataset S1.
(TIF)
Figure S6 Krssak2004 Postprandial hepatic glycogen
metabolism. Time courses of insulin, glucagon, glycogen and
endogenous glucose production/net HGP for mixed meal tests (left)
andhyperglycemic,hyperinsulinemic clamptests(right) inHumans.
Experimental data from [26] shown as black box with error bars
(experimental data extracted from figures and tables). (I)Blue curves
are model simulations with experimental glucose, insulin and
glucagon time courses as model input without using hormone dose
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glucose time course with predicted insulin and glucagon time
courses via the respective hormone dose response curves as model
input. In case of identical simulation results for (I) and (II) only the
blue curves are shown. Initial glycogen in the mixed meal
simulations are set to 275 mM glycogen and 220 mM glycogen in
the clamp simulation. Grey error estimations are based on model
simulations taking the errors in insulin and glucagon into account.
Predicted insulin, glucagon and glycogen time courses are in
agreementwiththeexperimentallyobservedtime courses.Predicted
time courses of glycogen and EGP are very similar for (I) and (II).
The glycogen synthesis rate in the clamp experiment is overesti-
mated by the model. Imperfect simulation of glycogen synthesis in
the mixed-meal and clamp simulations may be due to the fact that
throughout the model the phosphorylation state of all regulatory
enzymes was the same at given concentration of glucagon and
insulin. This assumption is a simplification which could be the
reason why the activation of the glycogen synthase was overesti-
mated in our simulations. The measured endogenous glucose
production (EGP) and the net hepatic glucose production (HGP) are
substantially different. The presented model is a model describing
the net hepatic output of the liver, not taking into account possible
simultaneous production and utilization of glucose within the liver,
for instance in periportal and perivenious regions.
(TIF)
Figure S7 Fast time course simulation: model concen-
trations. Time course of model metabolites during perturbations
in plasma glucose from initial 5 mM to 7 mM at t=0 min, from
7 mM to 3 mM glucose at t=10 min and from 3 mM back to the
initial 5 mM glucose at t=20 min. Respective fluxes are depicted
in Figure S8. Normal model simulations are shown in black. After
perturbation the model reaches the new quasi-steady state (only
slow change in glycogen) within minutes, even after strong
perturbations in blood glucose. To analyze the effect of the
hormonal regulation on the glycogen metabolism and to
distinguish the effects due to fast allosteric regulations from the
hormonal regulation, the model was simulated without changing
the phosphorylation state of the glycogen synthase (GS) and
glycogen phosphorylase (GP) during the glucose perturbations (red
model simulations). The reduced glycogen metabolism leads to an
accumulation of the glycolytic intermediates during hyperglycemia
due to an inability of the system to store the glucose. If both
simulations yield equal results only the red curve is visible.
(TIF)
Figure S8 Fast time course simulation: model fluxes.
Time course of model fluxes during glucose disturbance profiles.
The description of the glucose profile and the corresponding
concentration time courses are given in Figure S7. Even without
hormonal regulation the glycogen system is able to switch direction
between glycogen synthesis and glycogenolysis under hypoglycemia
as a consequence of the futile cycle in glycogen metabolism.
Hormonal regulation supports the inherent switching of directions
increasing the flux in the respective directions. GP decreased in
hypoglycemia and strongly increased in hypoglycemia.
(TIF)
Figure S9 Metabolic control analysis of HGP. Metabolic
response coefficients of the HGP/HGU flux (top), gluconeogen-
esis/glycolysis flux (middle) and glycogenolysis/glycogenesis flux
(bottom) for hypoglycemic conditions of 3 mM (left) and
hyperglycemic conditions of 8 mM (right) for various glycogen
concentrations. Analyzed were the effects of changes in Vmax
values of the enzymes of hepatic glucose metabolism on the steady
state fluxes under the given conditions. The main interesting
effects are: (i) The key enzymes depend strongly on the glucose
concentration, different enzymes change the HGP/HGU, gluco-
neogenesis/glycolysis and glycogen synthesis/glycogenolysis under
hypoglycemia and hyperglycemia. (ii) Different Vmax show the
main response on HGP/HGU, gluconeogenesis/glycolysis and the
glycogen metabolism (iii) The interconvertible enzymes show
strong responses to changes in the Vmax values (iv) Only a selected
number of enzymes has a strong response, the change in Vmax of
many enzymes results in almost no change in key glucose fluxes.
(TIF)
Text S1 Overview metabolites. The full metabolite name,
the used short name in the model, the and the respective
compartment are depicted. The Initial concentrations with the
respective references used for all simulations are either from
human or rat liver/hepatocytes. The concentrations are given in
more detailed table format in Dataset S1. In the case that no
compartment-specific data for mitochondrion was available, the
respective metabolite concentrations for cytosol were used. The
glycogen concentration is given in glucose equivalents.
(PDF)
Text S2 Overview reactions and transporters. The full
reaction/transporter name, the used short name in the model, the
and the respective compartment are depicted. The rate equations
of the kinetic model are given in Text S3. The given references are
the references for the kinetic parameters. Furthermore, the fitted
Vmax values used for simulations are given.
(PDF)
Text S3 Kinetic rate equations of the model. Detailed rate
equations of all processes of the model of human hepatic glucose
metabolism.
(PDF)
Text S4 Overview allosteric regulations. The respective
rate equations are given (Text S3). Allosterically regulated
enzymes characteristic for either HGP or HGU are marked
respectively. Allosteric regulators can function as activators are
inhibitors. The references stating the roles of the allosteric effectors
and the parameters in the rate equations are given.
(PDF)
Text S5 Overview interconvertible enzymes of human
hepatic glucose metabolism. Overview over the alterations in
kinetic properties as a consequence of changed phosphorylation
state between phosphorylated and dephosphorylated state of key
interconvertible enzymes of HGP and HGU.
(PDF)
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